# A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants

> **NCT04497883** · PHASE1 · COMPLETED · sponsor: **Shire** · enrollment: 24 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Maribavir (400 mg)
- **DRUG:** Maribavir (200 mg)
- **DRUG:** Maribavir (800 mg)

## Key facts

- **NCT ID:** NCT04497883
- **Lead sponsor:** Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-07
- **Primary completion:** 2020-11-12
- **Final completion:** 2020-11-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04497883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04497883, "A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04497883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*